Q1 Interim Report July 2024 – September 2024
OPENING REMARKS
The first quarter of the fiscal year 2024-2025 has been productive for Hamlet Biopharma. As summarized in the recently published Annual Report 2023-2024, significant clinical progress has been made in three different clinical areas - bladder cancer, recurrent acute cystitis and bladder pain. We are proud to have taken the investigational new drug Alpha1H from discovery, through the drug development process to the clinic. We are also proud to have identified new clinical indications for the IL-1 receptor antagonist anakinra, based on scientific precision and the identifications of IL-1 overactivation as a key disease mechanism.
During the first quarter, progress in the cancer therapeutics area was published in Cancer Medicine. The final analysis showed a strong clinical tumor response in patients with bladder cancer. The company has further made significant clinical progress in a randomized Phase II study of immunotherapy against a bacterial infection where the immuno-therapeutic drug anakinra showed therapeutic efficacy comparable to antibiotics. In addition, promising results for patients with bladder pain syndrome have been reported.
We have thus delivered on the promise to provide the market with data from these three studies and are now proceeding with the clinical and commercial development.
We are also excited about the new drug candidates in the company’s pipeline, which are advancing well, providing a high level of confidence for their continued development towards clinical trials. The progress confirms the expertise of our organization and our commitment to developing new treatments that address significant unmet medical needs and improve patient outcomes.
Hamlet BioPharma continues to drive the clinical programs forward with the goal of bringing these innovative therapies to market. Strategic alliances and commercial collaborations for our core assets in cancer and infections continue to be a key focus area for the company. The recent positive Phase II data puts renewed emphasis on the cancer and immunotherapy projects as well as the portfolio of preclinical projects.
We thank our shareholders for their commitment to the company and trust in our vision. We also thank our competent, multinational team as well as our external partners and experts for their invaluable contributions.
Catharina Svanborg Martin Erixon
Chairman of the Board Chief Executive Officer
SIGNIFICANT EVENTS DURING THE FIRST QUARTER
On August 22, 2024, Hamlet BioPharma announced the continuation of its series of digital investor meetings during the autumn. The meetings were scheduled to take place on September 18, October 23 and December 11, 2024, at 12:00 CET. The digital meetings are available at our website: https://hamletbiopharma.com/series-of-digital-events-2024/.
On August 27, 2024, Hamlet BioPharma invited to a press briefing where the year-end report (Q4) was presented. The meeting was scheduled to take place august 28, 2024.
On August 28, 2024, Hamlet BioPharma published the Year-end Report (Q4) July 2023 – June 2024.
On September 11, 2024, Hamlet BioPharma announced the publication of the full analysis of the Phase II clinical results in Cancer Medicine, https://doi.org/10.1002/cam4.70149. The article entitled "Clinical and molecular response to alpha1-oleate treatment in patients with bladder cancer" presents data confirming the effects of treatment compared to placebo. In addition, no significant drug-related adverse events were noted
On September 12, 2024, Hamlet BioPharma announced that The Economist, a leading international journal, had published an article on breast milk, mentioning and describing HAMLET and the clinical results. The article highlights the pioneering research work and the therapeutic properties of breast milk to treat cancer and other diseases. "This is an important recognition of our results and reinforces the relevance of our approach to developing new cancer treatments," says Catharina Svanborg from Lund University and Hamlet BioPharma.
On September 17, 2024, Hamlet BioPharma invited to a digital investor meeting taking place September 18 at 12:00 CET.
On September 26, 2024, Hamlet BioPharma announced new positive results from the Phase II clinical trial conducted in patients with recurrent bacterial urinary tract infections. The study compared antibiotic treatment with immunomodulatory therapy with anakinra (IL-1RA). Both treatments showed significant reductions in symptoms and improved quality of life, with no difference in efficacy between the two patient groups. Immunotherapy with anakinra may thus become an alternative to antibiotics and reduce the need for antibiotic treatment in this patient group.
SIGNIFICANT EVENTS AFTER THE FIRST QUARTER
On October 1, 2024, Hamlet BioPharma invited to a digital event to be held October 9th, where new exciting results from the company’s recently completed Phase II clinical study was presented. The study compared the effects of immunotherapy with antibiotic treatment in patients with recurrent bacterial infections.
On October 8, 2024, Hamlet Biopharma published a summary of the company’s three Phase II studies showing positive results for patients with recurrent acute cystitis treated with the Interleukin-1 receptor inhibitor anakinra, positive results for patients with severe bladder pain treated with the same substance, and positive results for patients with bladder cancer treated with the tumor-killing substance Alpha1H.
On October 24, 2024, the company published a notice of annual general meeting in Hamlet BioPharma AB, scheduled to take place on November 21th at 15:00 in Malmö.
On October 31, 2024, Hamlet BioPharma published the annual report for the fiscal year 2023/2024.
On November 4, 2024, Hamlet BioPharma was featured in CEO World Magazine, renowned for its focus on high-level executives and influential business leaders, in their latest Company Spotlight. They highlighted Hamlet BioPharma´s recent clinical trials and innovative approach merging groundbreaking research with a strong business vision.
The featured articles can be read here:
- https://ceoworld.biz/2024/10/29/interview-with-catharina-svanborg-of-hamlet-biopharma/#google_vignette
- https://pulse2.com/hamlet-biopharma-profile-professor-catharina-svanborg-interview/.
COMPANY OVERVIEW
Hamlet BioPharma is a pioneering biotechnology company focused on the development of innovative treatments for cancer and infectious diseases. With a mission to address large, unmet medical needs, the company has built a robust pipeline of therapeutic candidates targeting malignant tumors and antibiotic-resistant infections. The financial year 2023-2024 was transformational for Hamlet BioPharma, marked by significant regulatory and clinical milestones, as well as promising results in Phase II trials. These achievements underscore Hamlet BioPharma’s potential as a leader in biotechnology, advancing impactful therapies that respond to critical healthcare demands globally.
Key Developments
1. Alpha1H – Bladder Cancer Therapy
FDA IND Approval and Fast Track Designation: In July 2023, Hamlet BioPharma achieved a critical regulatory milestone with FDA approval of the Investigational New Drug (IND) application for Alpha1H, a synthetic peptide designed for the treatment of non-muscle invasive bladder cancer (NMIBC). By November, Alpha1H received Fast Track designation, enabling accelerated FDA support throughout clinical development. This designation validates Alpha1H’s promise in addressing NMIBC—a cancer subtype with high recurrence rates and limited treatment options.
- Phase II Clinical Success: Conducted in collaboration with a specialized clinic in Prague, Phase II clinical trials for Alpha1H revealed impressive anti-tumor activity. Results demonstrated dose-dependent efficacy, with 88% of patients treated with the higher dose experiencing partial or complete tumor responses. Furthermore, Alpha1H induced a positive immune response in patients, underscoring its dual potential as a tumor-targeting agent and an immunotherapeutic. This immune activation, a unique attribute of Alpha1H, holds promise in improving patient outcomes by engaging the body’s natural defences against cancer.
- Manufacturing and Scaling: To support upcoming Phase III trials and future commercialization, Hamlet BioPharma has strengthened its manufacturing infrastructure through partnerships with industry-leading facilities. Agreements with Polypeptide Group and Rechon Life Science ensure scalable production capabilities that align with Good Manufacturing Practices (GMP), essential for advancing Alpha1H toward widespread clinical use and, ultimately, market introduction. This groundwork reinforces Hamlet BioPharma’s readiness to meet clinical and commercial demands, placing Alpha1H on track for global distribution.
2. IL-1RA Immunotherapy – Addressing Infections and Inflammation
- Phase II Clinical Outcomes in Recurrent Cystitis: Antibiotic resistance presents a growing global challenge, particularly in managing recurrent bacterial infections like cystitis. Hamlet BioPharma’s immunotherapy, using the IL-1 receptor antagonist anakinra (IL-1RA), has emerged as a potential alternative to traditional antibiotic treatment. In Phase II trials conducted in Germany, IL-1RA was shown to be as effective as antibiotics in reducing symptoms and improving quality of life for patients with recurrent urinary tract infections. Importantly, IL-1RA treatment helps preserve the beneficial bacterial flora, reducing the risk of resistance and preserving long-term health outcomes.
- Market Differentiation: By focusing on an immunomodulatory approach, Hamlet BioPharma is offering an innovative solution to a significant medical need—antibiotic resistance. This treatment modality represents a paradigm shift in managing bacterial infections by enhancing the patient’s immune response rather than directly targeting the bacteria, reducing the selective pressure that contributes to resistance.
3. Strategic alliances and commercial partnerships
Hamlet BioPharma has engaged in strategic collaborations with leading international advisory firms, to identify partners for the commercialization of company assets. These partnership strategies have broadened our network within the industry, nationally and internationally. While discussions focus on the lead compound Alpha1H, recent positive Phase II data put renewed emphasis on the immunotherapy projects as well as the portfolio of preclinical projects, to identify new partnerships and strengthen existing networks.
Market Potential
The global demand for effective cancer therapies and alternative infection treatments is expanding, and Hamlet BioPharma’s drug candidates are well-positioned to capture substantial shares within these high-growth markets. With innovative solutions that align with current healthcare priorities, Hamlet BioPharma is addressing essential needs while positioning itself for sustainable growth.
1. Bladder Cancer Market
- Market Growth and Demand for Alternatives: Bladder cancer has one of the highest recurrence rates, with non-muscle invasive bladder cancer (NMIBC) being particularly challenging. This cancer type often requires repeated treatments, which are costly and have limited effectiveness. According to Transparency Market Research, the NMIBC market is projected to grow from USD 2.6 billion in 2023 to an estimated USD 21.1 billion by 2034, at a compound annual growth rate (CAGR) of 21.4%. This growth is driven by a growing focus on immunotherapies and the need for more effective, less invasive treatments.
- Alpha1H’s Market Position: Alpha1H, with its promising clinical outcomes and immune activation profile, is uniquely suited to meet the NMIBC market’s needs. As a Fast Track-designated therapy with documented anti-tumor effects, Alpha1H stands to become a valuable asset, in the global oncology market. Its innovative mechanism of action—targeting cancer cells while preserving healthy tissue—could make it a preferred alternative to traditional treatments, which are often associated with higher toxicity and frequent recurrences.
2. Infection Control and Antibiotic Alternatives
- Demand for Non-Antibiotic Solutions: The World Health Organization (WHO) has highlighted antibiotic resistance as one of the most urgent threats to public health. In the United States alone, the recurrent cystitis treatment market is valued at approximately USD 2 billion annually, with steady growth anticipated over the next decade. Driving this growth is the search for non-antibiotic therapies to manage infections, as antibiotic resistance continues to complicate treatment protocols. Analysts project a CAGR of 6-8% in this sector, with increasing demand for immunomodulatory therapies like IL-1RA.
- IL-1RA’s Potential: By harnessing the body’s immune response to combat infections, IL-1RA represents a safer, resistance-free alternative to antibiotics. It not only reduces infection symptoms but also preserves the beneficial microbiome, helping to counteract the rise of multi-drug-resistant infections. This makes IL-1RA an attractive option for patients, healthcare providers, and regulatory bodies alike.
4. Hamlet BioPharma’s pipeline
Hamlet BioPharma - the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections – has three projects in phase II clinical trials and promising assets in preclinical development, approaching the clinic.
The period in summary
FIRST QUARTER, JUL 1, 2024-SEPT 30, 2024 (THE PARENT COMPANY)
– Net sales totaled KSEK 0 (0)
– Other operating income totaled KSEK 0 (9)
– Loss before tax amounted to KSEK -9,766 (-8,329)
– Loss after tax amounted to KSEK -9,766 (-8,329)
– Loss per share* was SEK -0.0582 (-0.0661)
– On September 30, 2024, the equity/assets ratio** was 91.8 (86.8) %
FIRST QUARTER, JUL 1, 2024-SEPT 30, 2024 (THE GROUP)
– Net sales totaled KSEK 0 (0)
– Other operating income totaled KSEK 0 (9)
– Loss before tax amounted to KSEK -10,264 (-8,828)
– Loss after tax amounted to KSEK -10,264 (-8,828)
– Loss per share* was SEK -0.0612 (-0.0701)
– On September 30, 2024, the equity/assets ratio** was 91.4 (86.6) %
Amounts in parentheses above and below indicate the corresponding value in the preceding year.
* Profit/loss after tax for the period divided by 167,762,902 (112,006,368), respectively, where 167,762,902 is the number of shares outstanding on September 30, 2024, the comparative figure in parentheses was the number of shares on September 30, 2023.
** Equity divided by total capital.
Revenues and earnings
The costs for the merged companies Hamlet BioPharma and SelectImmune Pharma reflect the larger project portfolio and the costs of the three clinical trials in Phase II. Hamlet BioPharma’s net sales amounted to KSEK 0 (0) during the first quarter. Other operating income amounted to KSEK 0 (9) during the quarter. Costs were related to the continued drug development activities of the research team at Lund University. The team at Lund University is also responsible for the development of manufacturing methods, stability testing, and chemical and functional characterization of existing and new drug substances and plays a key role in the coordination of laboratory testing in the clinical trial. Costs were also related to manufacturing of the Alpha1H drug candidate, for use in ongoing and forthcoming clinical trials. Costs in the group accounting consists of depreciation of patent from the acquirement of Linnane Projects AB.
Loss before tax for the parent company for the first quarter was KSEK -9,766 (-8,329). Loss before tax for the group for the first quarter was KSEK -10,264 (-8,828).
Financial position
At the end of the first quarter, the equity/assets ratio was 91.8 (86.8) %, and the Company’s cash and cash equivalents were KSEK 16,516 (13,166).
The company assesses that there will be a need to raise capital during the financial year in order to secure continued operations.
Investments
The Company does not capitalize expenses for research and development as assets, since the Company is in an R&D stage. R&D costs are therefore recognized as operating expenses in the income statement.
Depreciation
During the quarter, depreciation of equipment amounted to KSEK 113 (73), and the depreciation of patents from the merger with SelectImmune Pharma AB amounted to KSEK 2,021 (1,152).
In the group, depreciation of patents, including the acquisition of Linnane Projects AB, amounted to KSEK 2,520 (1,651) during the quarter.
Employees
The company had the equivalent of 8 (7) full-time employees during the quarter
The share
The Company’s shares have been traded on Spotlight Stock Market since October 23, 2015. The share is traded under the short name “HAMLET B” with ISIN code SE0015661152.
At the extraordinary general meeting in Hamlet Pharma AB on March 2, 2021, it was decided that the company’s common shares would undergo a split with relation 3:1 and would be reclassified as A- and B-shares. The B-shares will be traded on Spotlight Stock Market. The A-shares will not be listed. Each A-share entitles to ten votes and B-shares entitles to one vote. Furthermore, it is possible for shareholders to convert A-shares to B-shares, which can be traded on Spotlight Stock Market. This conversion program is ongoing with no current deadline. This means that the ratio between A- and B-shares will change over time.
As of September 30, 2024, the number of shares registered at the Swedish Companies Registration Office (Bolagsverket) totaled 167,762,902.
As of November 13, 2024, the registered current ratio of shares was 39,965,160 A-shares and 127,797,742 B-shares.
Subscription warrants
The company had no outstanding warrants as of September 30, 2024.
Transactions with related parties
During the quarter, KSEK 1,370 (1,248) was paid to Linnane Pharma AB, of which KSEK 0 (35) refers to consulting fees, KSEK 0 (551) refers to the old agreement about the technology platform, KSEK 1,250 (417) refers to the new co-operation agreement, KSEK 120 (Hamlet Pharma: 40, SelectImmune Pharma AB: 205) refers to patent license.
The consulting fees to Linnane Pharma refers to compensation for the collaboration agreement access to advanced science and cutting-edge technology for drug development. The collaboration means that Linnane Pharma's technology platform and other resources are available to Hamlet BioPharma. Hamlet BioPharma is a subsidiary company of Linnane Pharma AB, which owns 36.31% of the capital and 76.26% of the votes of Hamlet BioPharma.
Furthermore, salaries and allowances to board and management were paid during the period. Transactions with related parties is on market terms.
Significant risks and uncertainties
The Board's assessment of significant risks and uncertainties is unchanged compared with the most recent financial year and are described in the most recently published annual report (2024-06-30).
Basis of preparation for the interim report
The Company prepares its accounts in accordance with the Swedish Annual Accounts Act (Årsredovisningslagen) and the K3 framework (BFNAR 2012:1) of the Swedish Accounting Standards Board (Bokföringsnämnden).
The company's accounting principles are unchanged compared with most recent financial year and are described in the most recent published annual report (2024-06-30).
On March 31st, 2023, Hamlet BioPharma acquired Linnane Projects AB from Linnane Pharma AB and the patents and know-how regarding a new peptide-based drug against tuberculosis as well as the know-how required to develop the project. In accordance with regulations at Spotlight and the Swedish Accounting Standards Board (Bokföringsnämnden), consolidated accounts of Linnane Projects and Hamlet BioPharma are drawn up. The quarterly report is prepared with the parent company’s accounting in focus. In texts, the group is only commented on if something differs significantly from the parent company.
Review
This interim report has not been audited.
Financial calendar
Annual General Meeting 2023/2024 2024-11-21
Half-yearly report 2024/2025 2025-02-13
Interim report 3 2024/2025 2025-05-22
Year-end report 2024/2025 2025-08-28
Annual report 2024/2025 2025-10-31
Interim report 1 2025/2026 2025-11-14
Annual General Meeting 2024/2025 2025-11-20
Income Statement : The Parent Company
|
|
2024-07-01 |
2023-07-01 |
2023-07-01 |
|
(SEK) |
2024-09-30 |
2023-09-30 |
2024-06-30 |
|
|
|
|
|
|
Net sales |
0 |
0 |
0 |
|
Other operating income |
0 |
8 511 |
29 971 |
|
Operating income |
0 |
8 511 |
29 971 |
|
|
|
|
|
|
Other external costs |
-5 746 076 |
-5 673 190 |
-25 220 121 |
|
Employee benefit expenses |
-2 044 324 |
-1 437 220 |
-7 712 231 |
|
Depreciation of assets |
-2 135 040 |
-1 224 449 |
-7 609 148 |
|
Other operating expenses |
-11 138 |
0 |
-27 545 |
|
Operating loss |
-9 936 578 |
-8 326 348 |
-40 539 074 |
|
|
|
|
|
|
Financial items |
170 986 |
-3 147 |
717 413 |
|
Loss before tax |
-9 765 592 |
-8 329 495 |
-39 821 661 |
|
|
|
|
|
|
Tax on loss for the period |
0 |
0 |
0 |
|
Loss after tax |
-9 765 592 |
-8 329 495 |
-39 821 661 |
Balance Sheet : The Parent Company
|
Assets, SEK |
2024-09-30 |
2023-09-30 |
2024-06-30 |
|
|
|
|
|
|
Fixed assets |
|
|
|
|
Intangible assets |
31 188 959 |
39 274 163 |
33 210 260 |
|
Tangible assets |
460 517 |
616 967 |
574 256 |
|
Financial assets |
10 000 000 |
10000000 |
10 000 000 |
|
Total fixed assets |
41 649 476 |
49 891 130 |
43 784 516 |
|
|
|
|
|
|
Current assets |
|
|
|
|
Other receivables |
3 514 975 |
1 228 410 |
3 727 639 |
|
Prepaid expenses |
621 912 |
250 909 |
471 474 |
|
Cash and bank balances/financial investments |
16 515 561 |
13 165 963 |
23 076 079 |
|
Total current assets |
20 652 448 |
14 645 282 |
27 275 192 |
|
|
|
|
|
|
Total assets |
62 301 923 |
64 536 412 |
71 059 708 |
|
|
|
|
|
|
|
|
|
|
|
Equity & Liabilities, SEK |
2024-09-30 |
2023-09-30 |
2024-06-30 |
|
|
|
|
|
|
Restricted equity |
|
|
|
|
Share capital |
1 677 629 |
1 260 064 |
1 677 629 |
|
Statutory reserve |
20 000 |
20 000 |
20 000 |
|
Total restricted equity |
1 697 629 |
1 280 064 |
1 697 629 |
|
|
|
|
|
|
Non-restricted equity |
|
|
|
|
Share premium reserve |
225 337 658 |
183 302 138 |
225 337 658 |
|
Retained earnings |
-160 083 493 |
-120 261 832 |
-120 261 832 |
|
Loss for the period |
-9 765 592 |
-8 329 495 |
-39 821 661 |
|
Total non-restricted equity |
55 488 573 |
54 710 812 |
65 254 165 |
|
|
|
|
|
|
Total equity attributable to the parent company's shareholders Total equity |
57 186 202 |
55 990 876 |
66 951 794 |
|
|
|
|
|
|
Non-current liabilities |
|
|
|
|
Liabilities to group companies |
0 |
5 000 000 |
0 |
|
Total non-current liabilities |
0 |
5 000 000 |
0 |
|
|
|
|
|
|
Current liabilities |
|
|
|
|
Accounts payable |
2 213 060 |
839 756 |
1 230 214 |
|
Tax liabilities |
81 052 |
78 210 |
181 994 |
|
Other liabilities |
597 996 |
429 634 |
297 279 |
|
Accrued expenses |
2 223 613 |
2 197 937 |
2 398 427 |
|
Total current liabilities |
5 115 721 |
3 545 536 |
4 107 914 |
|
|
|
|
|
|
Total Equity & Liabilities |
62 301 923 |
64 536 412 |
71 059 708 |
Cash Flow Statement : The Parent Company
|
Cash flow statement |
2024-07-01 |
2023-07-01 |
2023-07-01 |
|
(SEK) |
2024-09-30 |
2023-09-30 |
2024-06-30 |
|
|
|
|
|
|
Operating activities |
|
|
|
|
Loss after financial items |
-9 765 592 |
-8 329 495 |
-39 821 661 |
|
Adjusted for non-cash items, etc. |
2 135 040 |
1 224 449 |
5 838 114 |
|
Cash flow from operating activities |
|
|
|
|
before changes in working capital |
-7 630 552 |
-7 105 046 |
-33 983 547 |
|
|
|
|
|
|
Cash flow from changes in working capital |
|
|
|
|
Change in current receivables |
62 226 |
-858 087 |
-3 577 882 |
|
Change in current liabilities |
1 007 807 |
996 963 |
1 559 340 |
|
Cash flow from operating activities |
-6 560 518 |
-6 966 170 |
-36 002 089 |
|
|
|
|
|
|
Investing activities |
|
|
|
|
Acquisition of tangible assets |
0 |
0 |
-278 085 |
|
Acquisition of financial assets |
0 |
0 |
0 |
|
Cash flow from investing activities |
0 |
0 |
-278 085 |
|
|
|
|
|
|
Financing activities |
|
|
|
|
Rights issue |
0 |
0 |
46 767 318 |
|
Issuance costs |
0 |
0 |
-4 314 233 |
|
Borrowings |
0 |
0 |
0 |
|
Amortization of loans |
0 |
0 |
-5 000 000 |
|
Merger with SelectImmune Pharma AB |
0 |
1 764 278 |
3 535 312 |
|
Cash flow from financing activities |
0 |
1 764 278 |
40 988 397 |
|
|
|
|
|
|
Cash flow for the period |
-6 560 518 |
-5 201 892 |
4 708 224 |
|
|
|
|
|
|
Cash and cash equivalents at the beginning of the period |
23 076 079 |
18 367 855 |
18 367 855 |
|
Cash and cash equivalents at the end of the period |
16 515 561 |
13 165 963 |
23 076 079 |
Equity : The Parent Company
|
Equity (SEK) |
Share capital |
Statutory reserve |
Share premium reserve |
Retained earnings |
Loss |
Total |
|
Opening balance July 1, 2024 |
1 677 629 |
20 000 |
225 337 658 |
-120 261 832 |
-39 821 661 |
66 951 794 |
|
Transfer of prior year’s loss - Preliminary |
|
|
-39 821 661 |
39 821 661 |
0 |
|
|
Loss for the period, Q1 |
|
|
|
|
-9 765 592 |
-9 765 592 |
|
Equity September 30, 2024 |
1 677 629 |
20 000 |
225 337 658 |
-160 083 493 |
-9 765 592 |
57 186 202 |
Income Statement : The Group
|
|
2024-07-01 |
2023-07-01 |
2023-07-01 |
|
(SEK) |
2024-09-30 |
2023-09-30 |
2024-06-30 |
|
|
|
|
|
|
Net sales |
0 |
0 |
0 |
|
Other operating income |
0 |
8 511 |
29 971 |
|
Operating income |
0 |
8 511 |
29 971 |
|
|
|
|
|
|
Other external costs |
-5 746 076 |
-5 673 190 |
-25 220 121 |
|
Employee benefit expenses |
-2 044 324 |
-1 437 220 |
-7 712 231 |
|
Depreciation of assets |
-2 633 790 |
-498 750 |
-9 604 148 |
|
Other operating expenses |
-11 138 |
0 |
-27 545 |
|
Operating loss |
-10 435 328 |
-7 600 649 |
-42 534 074 |
|
|
|
|
|
|
Financial items |
170 986 |
-3 147 |
717 413 |
|
Loss before tax |
-10 264 342 |
-7 603 796 |
-41 816 661 |
|
|
|
|
|
|
Tax on loss for the period |
0 |
0 |
0 |
|
Loss after tax |
-10 264 342 |
-7 603 796 |
-41 816 661 |
|
Attributable to |
|
|
|
|
The parent company's shareholders |
-10 264 342 |
-7 603 796 |
-41 816 661 |
|
Holdings without controlling influence |
0 |
0 |
0 |
Balance Sheet : The Group
|
Assets, SEK |
2024-09-30 |
2023-09-30 |
2024-06-30 |
|
|
|
|
|
|
Fixed assets |
|
|
|
|
Intangible assets |
38 171 459 |
48 251 663 |
40 691 510 |
|
Tangible assets |
460 517 |
616 967 |
574 256 |
|
Financial assets |
0 |
0 |
0 |
|
Total fixed assets |
38 631 976 |
48 868 630 |
41 265 766 |
|
|
|
|
|
|
Current assets |
|
|
|
|
Other receivables |
3 514 975 |
1 228 410 |
3 727 639 |
|
Prepaid expenses |
621 912 |
250 909 |
471 474 |
|
Cash and bank balances/financial investments |
16 540 561 |
13 190 963 |
23 101 079 |
|
Total current assets |
20 677 448 |
14 670 282 |
27 300 192 |
|
|
|
|
|
|
Total assets |
59 309 423 |
63 538 912 |
68 565 958 |
|
|
|
|
|
|
|
|
|
|
|
Equity & Liabilities, SEK |
2024-09-30 |
2023-09-30 |
2024-06-30 |
|
|
|
|
|
|
Equity |
|
|
|
|
Share capital |
1 677 629 |
1 260 064 |
1 677 629 |
|
Other contributed capital |
225 357 658 |
183 322 138 |
225 357 658 |
|
Other equity including profit for the period |
-172 841 585 |
-129 588 826 |
-162 577 243 |
|
Total equity attributable to the parent company's shareholders |
54 193 702 |
54 993 376 |
64 458 044 |
|
Holdings without controlling influence |
0 |
0 |
0 |
|
Total equity |
54 193 702 |
54 993 376 |
64 458 044 |
|
|
|
|
|
|
Non-current liabilities |
|
|
|
|
Liabilities to group companies |
0 |
5 000 000 |
0 |
|
Total non-current liabilities |
0 |
5 000 000 |
0 |
|
|
|
|
|
|
Current liabilities |
|
|
|
|
Accounts payable |
2 213 060 |
839 756 |
1 230 214 |
|
Tax liabilities |
81 052 |
78 210 |
181 994 |
|
Other liabilities |
597 996 |
429 634 |
297 279 |
|
Accrued expenses |
2 223 613 |
2 197 937 |
2 398 427 |
|
Total current liabilities |
5 115 721 |
3 545 536 |
4 107 914 |
|
|
|
|
|
|
Total Equity & Liabilities |
59 309 423 |
63 538 912 |
68 565 958 |
Cash Flow Statement : The Group
|
Cash flow statement |
2024-07-01 |
2023-07-01 |
2023-07-01 |
|
(SEK) |
2024-09-30 |
2023-09-30 |
2024-06-30 |
|
|
|
|
|
|
Operating activities |
|
|
|
|
Loss after financial items |
-10 264 342 |
-8 828 245 |
-41 816 661 |
|
Adjusted for non-cash items, etc. |
2 633 790 |
1 723 199 |
7 833 114 |
|
Cash flow from operating activities |
|
|
|
|
before changes in working capital |
-7 630 552 |
-7 105 046 |
-33 983 547 |
|
|
|
|
|
|
Cash flow from changes in working capital |
|
|
|
|
Change in current receivables |
62 226 |
-858 087 |
-3 577 882 |
|
Change in current liabilities |
1 007 807 |
996 963 |
1 559 340 |
|
Cash flow from operating activities |
-6 560 518 |
-6 966 170 |
-36 002 089 |
|
|
|
|
|
|
Investing activities |
|
|
|
|
Acquisition of intangible assets |
0 |
0 |
0 |
|
Acquisition of tangible assets |
0 |
0 |
-278 085 |
|
Acquisition of financial assets |
0 |
0 |
0 |
|
Cash flow from investing activities |
0 |
0 |
-278 085 |
|
|
|
|
|
|
Financing activities |
|
|
|
|
Rights issue |
0 |
0 |
46 767 318 |
|
Issuance costs |
0 |
0 |
-4 314 233 |
|
Borrowings |
0 |
0 |
0 |
|
Amortization of loans |
0 |
0 |
-5 000 000 |
|
Merger with SelectImmune Pharma AB |
0 |
1 764 278 |
3 535 312 |
|
Cash flow from financing activities |
0 |
1 764 278 |
40 988 397 |
|
|
|
|
|
|
Cash flow for the period |
-6 560 518 |
-5 201 892 |
4 708 224 |
|
|
|
|
|
|
Cash and cash equivalents at the beginning of the period |
23 101 079 |
18 392 855 |
18 392 855 |
|
Cash and cash equivalents at the end of the period |
16 540 561 |
13 190 963 |
23 101 079 |
Equity : The Group
|
Equity (SEK) |
Share capital |
Other contributed capital |
Other equity incl profit for the period |
Total |
|
Opening balance July 1, 2024 |
1 677 629 |
225 357 658 |
-162 577 243 |
64 458 044 |
|
Transfer of prior year’s loss - Preliminary |
|
|
0 |
0 |
|
Loss for the period, Q1 |
|
|
-10 264 342 |
-10 264 342 |
|
Equity September 30, 2024 |
1 677 629 |
225 357 658 |
-172 841 585 |
54 193 702 |
The Board of Directors and the Chief Executive Officer assure that the interim report provides a true and fair view of the Company's operations, position, and results.
Malmö, November 15, 2024
Catharina Svanborg Martin Erixon
Chairman of the Board CEO
Bill Hansson Helena Lomberg
Board member Board member
Magnus Nylén Elisabeth Parker
Board member Board member
Ulla Trägårdh
Board member